open access

Vol 27, No 1 (2020)
Editorial
Published online: 2020-02-25
Get Citation

To drop or not to drop the antiplatelet agent, that is the question for patients with atrial fibrillation and chronic coronary syndrome undergoing percutaneous coronary intervention

Yongcheol Kim, Thomas W. Johnson, Young-Hoon Jeong
DOI: 10.5603/CJ.2020.0012
·
Pubmed: 32103476
·
Cardiol J 2020;27(1):1-3.

open access

Vol 27, No 1 (2020)
Editorial
Published online: 2020-02-25

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

To drop or not to drop the antiplatelet agent, that is the question for patients with atrial fibrillation and chronic coronary syndrome undergoing percutaneous coronary intervention

Journal

Cardiology Journal

Issue

Vol 27, No 1 (2020)

Article type

Editorial

Pages

1-3

Published online

2020-02-25

DOI

10.5603/CJ.2020.0012

Pubmed

32103476

Bibliographic record

Cardiol J 2020;27(1):1-3.

Authors

Yongcheol Kim
Thomas W. Johnson
Young-Hoon Jeong

References (10)
  1. Lip GYH, Collet JP, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2019; 21(2): 192–193.
  2. Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016; 375(25): 2423–2434.
  3. Cannon C, Bhatt D, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017; 377(16): 1513–1524.
  4. Lopes R, Heizer G, Aronson R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019; 380(16): 1509–1524.
  5. Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019; 394(10206): 1335–1343.
  6. Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation. Circulation. 2019; 139(5): 604–616.
  7. Yasuda S, Kaikita K, Akao M, et al. AFIRE Investigators. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019; 381(12): 1103–1113.
  8. Huo Y, Jeong YH, Gong Y, et al. 2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Science Bulletin. 2019; 64(3): 166–179.
  9. Franchina AG, Calderone D, D'Arrigo P, et al. Mechanisms of ST-segment elevation myocardial infarction in patients with atrial fibrillation, prior stenting and long-standing chronic coronary syndrome. Cardiol J. 2020; 27(1): 8–15.
  10. Urban P, Mehran R, Colleran R, et al. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation. 2019; 140(3): 240–261.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl